What is DBV Technologies?
Founded in 2002 and headquartered in Montrouge, France, with a significant presence in New York, DBV Technologies operates as a specialized bio-pharmaceutical enterprise. The company is dedicated to the research and development of innovative medical treatments, focusing on high-impact healthcare solutions. As a B2B entity, it bridges the gap between complex scientific discovery and clinical application, leveraging its dual-continent operational structure to influence the global biopharmaceutical landscape. Its market position is defined by a commitment to rigorous clinical research and the development of specialized health technologies that address unmet medical needs.
How much funding has DBV Technologies raised?
DBV Technologies has raised a total of $808.3M across 9 funding rounds:
Series B
$6.6M
Series C
$25.5M
Stock Offering
$44.5M
Share Placement
$33.9M
Stock Offering
$153.7M
Share Placement
$194M
Other Financing Round
$306.9M
Stock/Share Issuance
$30M
Series B (2009): $6.6M led by ALK-Abello and Sofinnova Partners
Series C (2011): $25.5M supported by ALK Abello, InnoBio Fund, Sofinnova Partners, Lundbeckfonden Ventures, Shire Pharmaceuticals, and Alto Invest
Stock Issuance/Offering (2012): $44.5M, investors not publicly disclosed
Share Placement (2013): $33.9M backed by ALK Abello, Innobio, Apax Partners, Lundbeckfond, and Altamir
Stock Issuance/Offering (2020): $153.7M, investors not publicly disclosed
Share Placement (2022): $194M, investors not publicly disclosed
Other Financing Round (2025): $306.9M supported by Adage Capital Management, Bpifrance, MPM BioImpact, Yiheng Capital, Octagon Capital Group, Vivo Capital, Surveyor Capital, and Janus Henderson Investors
Stock/Share Issuance (2025): $30M, investors not publicly disclosed
Key Investors in DBV Technologies
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. The firm acts as a hands-on company builder across the entire value chain of life sciences investments.
Apax Partners
Apax Partners LLP is a global private equity advisory firm that supports the growth of businesses with strong long-term potential in the technology and services sectors.
Bpifrance
Founded in 2012, Bpifrance is a French public investment bank that finances companies at every stage of their development through credit, guarantees, and equity.
What's next for DBV Technologies?
Looking ahead, the recent capital influx is expected to catalyze the next phase of the company's lifecycle, transitioning from intensive research to broader commercialization strategies. The strategic focus will likely center on scaling clinical trial operations and optimizing the delivery of its medical technologies to global markets. By leveraging the expertise of its diverse investor base, DBV Technologies is poised to enhance its operational efficiency and strengthen its competitive advantage within the highly regulated and capital-intensive biopharmaceutical industry.
See full DBV Technologies company page
